{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-040675","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.372435+00:00","generated_at":"2026-06-04T03:12:54.105058+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amarin extends VAZKEPA European patent exclusivity to 2039; defends 2033 patent","bullets":["EPO granted new VAZKEPA patent covering REDUCE-IT protocol/results, extending exclusivity to April 2039.","Amarin successfully defended separate VAZKEPA patent (expires June 2033) against third-party opposition at EPO.","Legacy patent exclusivity from ANCHOR study extended via SPCs until June 2035.","Regulatory exclusivity for VAZKEPA in Europe runs until March 2031, layering with patent protections.","CEO Patrick Holt says extended runway enhances commercial and growth potential for VAZKEPA in Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-040675","json":"https://secwatch.observer/filing/0000950170-24-040675.json","markdown":"https://secwatch.observer/filing/0000950170-24-040675.md","text":"https://secwatch.observer/filing/0000950170-24-040675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017024040675/0000950170-24-040675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017024040675/amrn-20240403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:12:54.105058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}